

Enhancing the BOADICEA cancer risk prediction model to incorporate new data on *RAD51C*, *RAD51D*, *BARD1*, updates to tumour pathology and cancer incidences.

Andrew Lee¹, Nasim Mavaddat¹, Alex P. Cunningham¹, Tim Carver¹, Stephanie Archer², Fiona M. Walter^{2,3}, Marc Tischkowitz⁴, Jonathan Roberts⁴, Juliet Usher-Smith², Jacques Simard⁵, Marjanka K. Schmidt⁶, Peter Devilee⁷, Vesna Zadnik⁸, Hannes Jürgens⁹, Emmanuelle Mouret-Fourme¹⁰, Antoine De Pauw¹¹, Matti Rookus¹², Thea M. Mooij¹², Paul P.D. Pharoah^{1,13}, Douglas F. Easton^{1,13}, Antonis C. Antoniou^{1,†}

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, The University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK

²The Primary Care Unit, Department of Public Health & Primary Care, The University of Cambridge, Cambridge, CB1 8RN, UK

³Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK

⁴Department of Medical Genetics and National Institute for Health Research, Cambridge Biomedical Research Centre, The University of Cambridge, Cambridge, UK

⁵Centre Hospitalier Universitaire de Québec–Université Laval Research Center, 2705 Laurier Boulevard, Québec City, QC, G1V4G2, Canada

⁶Division of Molecular Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

⁷Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

⁸Epidemiology and Cancer Registry, Institute of Oncology, Ljubljana, Slovenia

⁹Tartu University Hospital, Clinic of Hematology & Oncology, Puusepa 8, Tartu, Estonia

¹⁰Service de Génétique, Institut Curie, 35, rue Dailly, Saint-Cloud, 92210, France

¹¹Service de Génétique, Institut Curie, 26, rue d'Ulm, Paris, 75005, France

¹²Department of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, 1006 BE Amsterdam, The Netherlands

¹³Centre for Cancer Genetic Epidemiology, Department of Oncology, The University of Cambridge, Cambridge CB1 8RN, UK

[†]**Corresponding author:** Antonis C. Antoniou, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK, aca20@medschl.cam.ac.uk, +44 1223 748630

ORCID ID: 0000-0001-9223-3116

Key Words: breast cancer, ovarian cancer, risk, *RAD51C*, *RAD51D*, *BARD1*, *PALB2*, BOADICEA, CanRisk

Word Count: 4102

Abstract

Background

BOADICEA for breast cancer and the epithelial ovarian cancer (EOC) models included in the CanRisk tool (www.canrisk.org) provide future cancer risks based on rare pathogenic variants in cancer-susceptibility genes, polygenic risk scores, breast-density, questionnaire-based risk factors and family history. Here, we extend the models to include the effects of pathogenic variants in recently established breast cancer and EOC susceptibility genes, up-to-date age-specific pathology distributions and continuous risk factors.

Methods

BOADICEA was extended to further incorporate the associations of pathogenic variants in *BARD1*, *RAD51C* and *RAD51D* with breast cancer risk. The EOC model was extended to include the association of *PALB2* pathogenic variants with EOC risk. Age-specific distributions of oestrogen-receptor-negative and triple-negative breast cancer status for pathogenic variant carriers in these genes and *CHEK2* and *ATM* were also incorporated. A novel method to include continuous risk factors was developed, exemplified by including adult-height as continuous.

Results

BARD1, *RAD51C* and *RAD51D* explain 0.31% of the breast cancer polygenic variance. When incorporated into the multifactorial model, 34-44% of these carriers would be reclassified to the near-population and 15-22% to the high-risk categories based on the UK NICE guidelines. Including height as continuous, increased the BC relative-risk variance from 0.002 to 0.010.

Conclusions

These extensions will allow for better personalised risks for *BARD1*, *RAD51C*, *RAD51D* and *PALB2* pathogenic variant carriers and more informed choices on screening, prevention, risk factor modification or other risk-reducing options.

Introduction

Breast cancer (BC) and epithelial tubo-ovarian cancer (EOC) are two of the most common cancers in females^{1 2}. Through mammography or other methods, screening for BC can reduce mortality, and organised screening is available in most developed countries³. For EOC, no effective screening exists, but the disease can be prevented by salpingo-oophorectomy. However, these preventative options are associated with adverse effects. Therefore, identifying those at increased risk may help to target screening and preventative options to those most likely to benefit⁴. Both BC and EOC risks are multifactorial diseases, with family history of cancer (FH), genetic factors and lifestyle, hormonal and reproductive risk factors (RF) all contributing to risk⁵⁻⁷.

Previously we developed the BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) model for BC risk prediction and for the likelihood of carrying pathogenic variants (PVs) in BC susceptibility genes. BOADICEA v5 incorporates the effects of PVs in five BC susceptibility genes (*BRCA1*, *BRCA2*, *PALB2*, *CHEK2* and *ATM*), the effects of known common genetic variants summarised as a polygenic risk score (PRS), and a polygenic component that accounts for any residual familial aggregation^{8 9}. We also developed a similar EOC model (Ovarian Cancer Model v1) that considers the effects of PVs in *BRCA1*, *BRCA2*, *RAD51D*, *RAD51C* and *BRIP1* on EOC together with a polygenic component^{10 11}. BOADICEA includes mammographic density and both models incorporate the effects of known lifestyle, hormonal, reproductive and anthropometric RFs. In addition, the models incorporate breast tumour heterogeneity by considering the distributions of tumour oestrogen receptor (ER) and triple-negative (TN) (ER, progesterone receptor and human epidermal growth factor receptor 2 negative) status for *BRCA1* and *BRCA2* PV carriers and the general population^{12 13}. Both models are freely available to healthcare professionals via the CanRisk webtool (www.canrisk.org), and are widely used by healthcare professionals¹⁴.

Recently, large population-based and family-based targeted sequencing studies have established that PVs in *RAD51C*, *RAD51D* and *BARD1* are associated with BC risk^{15 16} and that PVs in *PALB2* are associated with EOC risk^{17 18}. In addition, analysis of the tumour

characteristics in the BRIDGES study has provided age-specific estimates of the distributions of tumour characteristics for PV carriers in all established susceptibility genes¹⁹.

A further limitation of the previous models is that all epidemiological RFs are treated as categorical. However, some RFs (e.g., height, body mass index (BMI) mammographic density) are intrinsically continuous, and discretisation results in a loss of information, reducing their predictive ability.

Here we extend both models to explicitly model the effects of PVs in the recently established BC and EOC susceptibility genes and incorporate up-to-date age-specific pathology distributions. We present a methodological framework for incorporating continuous RFs into the model, and we demonstrate this by including height as a continuous variable. Finally, we describe updates to the population reference cancer incidences used in the models by incorporating more up-to-date incidences, incidences for additional countries and refining the derivation of birth-cohort specific incidences for inclusion in the models that address sparsity in the population incidence data.

Methods

Rare Moderate-Risk Pathogenic Variants

Both BOADICEA and the EOC Model model cancer incidence as an explicit function of PVs in known high- and moderate-penetrance susceptibility genes (major genes) together with a polygenic component^{9-12 20-22}. By using an explicit genetic model, they can account for both genetic testing and detailed FH. BOADICEA includes the genes *BRCA1*, *BRCA2*, *PALB2*, *CHEK2* and *ATM*, with dominance in that order, along with a BC susceptibility polygenic component. The EOC Model includes the genes *BRCA1*, *BRCA2*, *RAD51D*, *RAD51C* and *BRIP1*, with dominance in that order, along with an EOC susceptibility polygenic component. Details of the underlying model are included in the supplementary material. The values of the parameters for the original models were determined by complex segregation analysis^{9 10}. However, this was not possible for the extended versions since no sufficiently large data set containing all the model features was available. Instead, we adopted a synthetic approach²³, in which additional model parameters are taken from large-scale external studies^{8 11 12 21}.

Here, BOADICEA was extended to explicitly model the effects of PVs in *BARD1*, *RAD51C* and *RAD51D* (eight BC susceptibility genes), while the EOC model was extended to include *PALB2* (six EOC susceptibility genes). In both models, the effects of PVs were included as major genes and are parameterised by their allele frequency in the general population and their age-specific relative risks (RR). The BC RR for carriers of PV in *BARD1* was taken from the BRIDGES study¹⁵, while those for *RAD51C* and *RAD51D* were the meta-analysed values from Dorling et al¹⁵ and Yang et al²⁴. The EOC RR for *PALB2* PV carriers was taken from Yang et al¹⁷. Updated RRs for carriers of PV in *ATM*, along with PV carrier frequencies for *PALB2*, *CHEK2*, *ATM*, *BARD1*, *RAD51D*, *RAD51C* and *BRIP1* and screening test sensitivities for all genes were derived from Dorling et al¹⁵. We used the BRIDGES study to derive these frequency estimates as it is a very large population-based dataset that includes targeted sequencing data. Frequencies were based on the control frequencies in European populations, adjusted for the assumed sensitivity of the sequencing and the fact that large rearrangements were not detected (supplementary material). The default sensitivities were then calculated, assuming that clinical genetic testing will detect all known pathogenic mutations except for large rearrangements (except *BRCA1* and *BRCA2*, where testing for large rearrangements is routinely done). All model parameters for PVs are given in Table 1.

As the polygenic component captures all residual familial aggregation not explained by the major genes, the previous models implicitly included the contributions of PVs in the new genes (i.e., *BARD1*, *RAD51C* and *RAD51D* for BOADICEA and *PALB2* for the EOC Model). Therefore, to avoid double counting their contribution, it was necessary to remove their contribution from the polygenic component by adjusting the log-RR per standard deviation of the polygenic component such that the total variance of the polygenic component and the new genes is the same as that of the polygenic component of the previous model²¹ (supplementary material).

The association between *PALB2* PVs and EOC was also included in the BOADICEA model, and the associations with male BC and PaC have been included in both models¹⁷.

The effects of PV in the new BC susceptibility genes on risk prediction were assessed by considering the risk categories described in the National Institute for Health and Care Excellence (NICE) familial BC guidelines²⁵. For lifetime risk (age 20 to 80 years), three categories are defined: 1) near-population-risk, for risks less than 17%, 2) moderate-risk, for risks in the range [17%, 30%) and 3) high-risk, for risks of 30% or greater. Reclassification was considered based on questionnaire-based RFs (QRF) (RFs other than mammographic density), mammographic density (MD, based on the BI-RADS system) and a polygenic risk score (PRS). For BC, the PRS was taken to be the Breast Cancer Association Consortium 313 variant PRS, which accounts for 20% of the overall polygenic variance^{8 26}. For EOC, we defined three risk categories based on lifetime risk^{27 28}: 1) near-population-risk, for risks of less than 5%, 2) moderate-risk, for risks in the range [5%, 10%) and 3) high-risk, for risks of 10% or greater, and reclassification was considered based on RFs and a PRS. For EOC, the PRS was taken as the Ovarian Cancer Association Consortium 36 variant PRS, which accounts for 5% of the overall polygenic variance^{11 29}.

Updates to Tumour Pathology

Both models incorporate data on BC tumour pathology, specifically ER and TN. The distribution of pathology for affected carriers of PVs differs substantially from that in non-carriers for several genes, so that pathology data can affect the carrier probabilities and hence cancer risks^{11 12}. In BOADICEA and the EOC model, breast tumours are classified into five groups based on ER and TN status: ER unknown, ER-positive, ER-negative/TN unknown, ER-negative/not TN, and TN. Previously, the models achieved this using age-dependent distributions in the general population and *BRCA1* and *BRCA2* PV carriers and an age-independent distribution for *CHEK2* PV carriers^{12 21}. Due to a lack of data, the tumour ER distribution for carriers of PV in other genes was assumed to be the same as the general population. Here, the models have been updated to incorporate age-dependent ER and TN tumour distributions for carriers of PVs in the BC susceptibility genes *PALB2*, *CHEK2*, *ATM*, *BARD1*, *RAD51C* and *RAD51D*, using data from BRIDGES¹⁹.

Continuous Risk Factors

The previous versions of the models included reproductive, lifestyle, hormonal and anthropometric RFs^{8,11}. One limitation of these models was that the RFs needed to be coded as categorical variables. Some RFs are naturally continuous, requiring prior discretisation to a finite number of categories, resulting in some loss of information and reduction in risk discrimination. Here, the methodology was extended to allow the inclusion of continuous risk factors.

The key challenge is to calculate the baseline incidences $\lambda_0(t)$ in equation (1) (supplementary material) from the population incidence and the risk factor distributions. The baseline incidences are calculated sequentially for each age t (considered discrete) using the values at age $t - 1$, starting from age 0, requiring the evolution with age of the probability distribution of those who are disease-free³⁰. For discrete factors/genes, this involves summing over all possible categories/genotypes, but for continuous factors/genes, it would involve integrating over all possible values. In principle, these integrals could be computed (either analytically or numerically). However, at each age, the number of terms in the integrand increases by a factor of 2, so by age 80, there are $>10^{24}$ terms, with evaluation becomes impracticable. Alternatively, the risk factor could be discretised into a very large number of categories. This would give a very close approximation to the continuous distribution, but (particularly once multiple risk factors are considered, as here) the large number of categories would also make the calculations impractical. Instead, we propose an alternate approach in which the continuous factors are discretised with categories adapted according to the observed RF. The approach is as follows:

1. Firstly, discretise the range of possible risk factor values into a finite number (n) of bins and calculate the probability mass and RR for each bin from the probability density and RR function for the continuous RF. This part is identical to the standard approach for discretising risk factors, used in the existing models⁸. For a risk factor, x , with probability density $P(x)$ and relative risk $RR(x)$ the probability mass for bin i with range $[l_i, u_i]$ is:

$$P(i) = \int_{l_i}^{u_i} P(x) dx, \quad (2)$$

and the corresponding RR is

$$RR(i) = \frac{1}{P(i)} \int_{l_i}^{u_i} RR(x) P(x) dx. \quad (3)$$

2. Create an additional $(n + 1)^{th}$ bin based on the individual's measured risk factor value that has an infinitesimal width. The RR for this bin is taken as the RR at the measured value, and it has zero mass. As this bin is infinitesimal, its overlap with the other bins is zero, so there is no double-counting.

This procedure creates a categorical risk factor with $n + 1$ categories, where the individual is assigned to the $(n + 1)^{th}$ category defined in step 2. This allows the exact value of the risk for the individual to be used, while the number of categories required to compute the baseline rates is fixed, limiting the computation time.

The accuracy of the approximation in the procedure relies on the assumption that the range of values within each bin have similar RRs, which should be reflected in the choice of discretisation scheme and the number of bins n . These choices will depend on the shape of the distribution and the RR function.

The above procedure can be applied to any risk factor distribution or RR function. However, the process assumes that an individual's position within the distribution is fixed with respect to age, although the value of the risk factor and RR may vary with age. Here, the method was applied to height.

Updates to Population Incidences

The baseline incidences in equation (1) are birth-year and country specific as a consequence of using birth-year and country-specific population incidences in the constraining process. We refined the derivation of cohort-specific population incidences to account for variability in the incidences due to small numbers. In addition, we have updated existing incidences in the model to include more recent calendar periods and adapted the model to utilise cancer

incidences from four new populations: the Netherlands, France, Slovenia and Estonia. Details are included in the supplementary material.

Results

Rare Moderate-Risk Pathogenic Variants

Table 1 summarises the models' genetic parameter estimates, including those for the new genes. The estimated cumulative age-specific BC risks for *BARD1*, *RAD51C* and *RAD51D* PV carriers in BOADICEA and EOC risks for *PALB2* carriers, assuming the UK incidences applicable to those born in the 1980s, are shown in figure 1. The estimated average lifetime BC risks for PV carriers are 24%, 22% and 21% for *BARD1*, *RAD51C* and *RAD51D* PV carriers, respectively. The estimated lifetime EOC risk for *PALB2* carriers is 5.0%. Based on the assumed allele frequencies, 0.22% of the population carry PV in the genes *BARD1*, *RAD51C* or *RAD51D*, and these explain on average 0.31% of the female BC polygenic variance (averaged over all ages and cohorts, weighted by the age- and cohort-specific BC incidences). Approximately 0.13% of the population carry PVs in *PALB2*, explaining 0.16% of the EOC polygenic variance and 2.5% of the male BC polygenic variance.

Figure 2 (a)-(f) and Supplementary Table s1 show the distributions of lifetime BC risks for carriers of PVs in *BARD1*, *RAD51C* and *RAD51D* for a female with unknown FH and a female whose mother is affected at age 50 based on PV carrier status alone and including QRF, MD and a PRS. Based solely on PV carrier status, all females with unknown FH would be classified as at moderate risk. When information on QRF, MD or PRS is known, there is significant reclassification to near-population and high-risk categories, which is greatest when all factors are used in combination. For example, based on lifetime BC risks and using the full multifactorial model incorporating QRF, MD and a PRS, 33.9% of *BARD1* PV carriers with unknown FH would be reclassified from moderate-risk to near-population-risk, and 21.9% would be reclassified to high-risk (Supplementary Table s1). Similarly, *BARD1* PV carriers with an affected first-degree relative would be considered high-risk (risk of 33.7% by age 80) based on family history and PV status alone. Incorporating the other risk factors would reclassify 12% as near-population risk and 40.2% as moderate-risk (Supplementary Table s1).

Figure 2 (g) and (h) and Supplementary Table s2 show the distribution of lifetime EOC risks for carriers of PVs in *PALB2* for a female with unknown FH and a female whose mother is affected at age 50, as a function of the RFs and PRS. For a *PALB2* carrier with unknown FH, when the RFs and PRS are considered jointly, 62.4% are classified as near-population-risk, 34.9% as moderate-risk, and 2.7% as high-risk. The corresponding proportions with an affected mother are 11.2%, 55.8%, and 33%, respectively. However, even among *PALB2* carriers with an affected mother, 97.5% will have risks of less than 3% by age 50 (Supplementary Table s2).

Tumour Pathology

Figure 3 and Supplementary Tables s3 and s4 show the age-specific distributions of ER-negative tumours and TN tumours among ER-negative tumours used in the models for *PALB2*, *ATM*, *CHEK2*, *BARD1*, *RAD51C* and *RAD51D* PV carriers based on the BRIDGES data¹⁹. *BARD1*, *RAD51C* and *RAD51D* PV carriers predominantly develop ER-negative BCs, and the proportions decrease with increasing age. On the other hand, *CHEK2* and *ATM* carriers primarily develop ER-positive BCs, and the proportion of ER-positive tumours increases with age. Among those with ER-negative tumours, most tumours are TN for PV carriers in all genes, except *CHEK2* carriers, in whom the majority are ER-negative but not TN.

Using the updated age- and gene-specific ER-negative and TN tumour status distributions resulted in differences in the predicted carrier probabilities by different tumour pathology and age (Figure 4). For *ATM*, the carrier probabilities for ER-negative tumours are reduced relative to previous estimates, reflecting the stronger association with ER-positive disease. Carrier probabilities for *CHEK2* now show a decline with age for ER-negative tumours (previously, this was only predicted for ER-positive disease). The carrier probabilities for *PALB2* remain similar to previous estimates. For the new genes *BARD1*, *RAD51C* and *RAD51D*, the carrier probabilities are, as expected, higher for ER-negative and TN disease, but there is little variation by age.

Continuous Risk Factors

As previously, adult female height was assumed to be normally distributed with mean 162.81cm and standard deviation 6.452cm, and be associated a log-RR per standard deviation, for both breast and ovarian cancer, of $0.10130^{8,11}$. We therefore discretised the normal distribution such that the probability masses of the bins were given by a binomial distribution $B(n - 1, \frac{1}{2})$, giving sufficient discretisation to adequately capture the tails of the distribution. We examined the relative discretisation error of the predicted lifetime risk as a function of the number of bins (Figure 5 e and f) and chose $n = 5$, as the lowest number of bins such that the root-mean-square relative error was less than 10^{-4} . Compared to the discrete (five-level) RF, the variance of the RR of both BC and EOC increased from 0.002 to 0.010 when height was included as a continuous RF. The effects on predicted lifetime risks are shown in Figure 5 (a)-(d). Under the continuous implementation here, the lifetime BC risk varied from 9.7% for the first percentile to 14.6% for the 99th, whereas under the previous discrete distribution, the risks range from 10.1% to 14.2%.

Discussion

This work has extended the multifactorial BOADICEA BC and EOC risk prediction models (BOADICEA v6 and the Ovarian Cancer Model v2), employing a synthetic approach²³. The explicit effects of PVs in *RAD51C*, *RAD51D*, *BARD1* and *PALB2*, which are now commonly included on cancer gene panels, are now included in the models. The models have also been extended to accommodate continuous RFs, and parameterisation of tumour pathology and cancer incidences have been updated with more recent data. These represent the most comprehensive models for BC and EOC and will allow more complete BC and EOC risk assessment of those undergoing gene-panel testing.

By explicitly modelling the effects of PVs in the new cancer susceptibility genes, the models provide personalised cancer risks of PV carriers when combined with QRFs, MD and PRS. Although the number of women affected by these changes will be small at population level, for women with *RAD51C*, *RAD51D* and *BARD1* PVs and their families, the updated risks will be clinically important. *RAD51C*, *RAD51D* and *BARD1* (like *ATM* and *CHEK2*) would be classified as “moderate risk” BC genes based on the average risks¹⁵. However, according to the

BOADICEA predictions, over half (56-59%) of carriers of PVs in these genes would be reclassified from moderate BC risk category to either near-population-risk (34-44%) or high-risk (15-22%), if data on the other risk factors were incorporated (Table s1). Such changes may have important implications for discussions around earlier or more frequent screening or on risk-reduction options for these women. Similarly, based on the multifactorial EOC model, *PALB2* PV carriers without EOC family history will always have EOC risks <3% by age 50. However, ~38% of *PALB2* PV carriers will have lifetime EOC risks of >5% (Table s2), which may influence recommendations on the timing of risk-reducing surgery.

As previously, the models assume that the effects of the PVs in the new genes interact multiplicatively with the PRS and the RFs. No studies have yet assessed the joint effects of PVs in these genes and the PRS or RFs. Previous results for *CHEK2* and *ATM* suggest that the multiplicative model holds true for earlier versions of the PRS³¹⁻³³. Unlike *CHEK2* and *ATM*, however, the new genes predispose more strongly to ER-negative disease, and the combined effect may depart from the multiplicative assumption. Demonstrating this explicitly for the new genes will be challenging given the rarity of the mutations. The multiplicative model has also been shown to be reasonable for the combined effects of PRS and RFs³⁴, but there is as yet no large-scale evaluation of the combined effects of PVs and RFs. However, recent prospective validation studies of the current and previous versions of the models suggest that, overall, the models fit well¹¹[Yang et al. under review]. Should deviations from the multiplicative model between these PVs and RFs emerge, the model can be updated to take them into account.

Both the BC and EOC models incorporate PVs' effects using the estimated population allele frequencies and RRs. These are combined with reference population incidences to calculate absolute risks while constraining the overall incidences over the RFs included in the model. Our implementation used RR and allele frequency estimates from the largest available studies on those of European ancestry¹⁵. These were assumed to be constant across all countries. Available data are currently too sparse to obtain country-specific estimates. Although there is no evidence that RRs vary among populations, the allele frequencies are likely to vary to some extent¹⁵. This is most apparent for *CHEK2*, where the founder c.1100delC variant is common in northwest Europe and explains the majority of carriers but

is rare or absent in other populations. If population-specific variants can be generated, the model can be easily updated to accommodate these. Nevertheless, by allowing population incidences to vary by country, the predicted absolute risks given by the models are country-specific.

The updated age-specific distributions of tumour ER and TN status for six of the BC susceptibility genes in the model (*PALB2*, *CHEK2*, *ATM*, *BARD1*, *RAD51C* and *RAD51D*) should allow better differentiation between PVs that may be present in a family. Since PV carrier probabilities are used internally in the models, these will also impact the predicted absolute risks for all unaffected individuals if information on tumour characteristics is available for affected relatives whether or not they carry a PV.

We have developed a novel methodological approach for including continuous RFs into the models. We demonstrated this by including height in both the BC and EOC models, allowing for more nuanced predictions and improving the risk discrimination. While the resulting discrimination based on height alone is modest, the framework will allow other more predictive RFs to be included in the model if accurate risk estimates become available. The most important example is MD: continuous measures of MD, available through tools such as STRATUS, CUMULUS and Volpara³⁵⁻³⁷, have been shown to have stronger associations with BC risk than the categorical BI-RADS system. Other examples include BMI and ages at menarche and menopause. Further, the method could be applied to the joint distribution of several continuous risk factors, where the integrals in equations (2) and (3) become multidimensional integrals.

We have further refined the method for creating cohort incidences from calendar period incidences (supplementary material). The approach provides incidences that are less sensitive to year-on-year fluctuations by averaging over all years in the birth cohort. This method is particularly useful for cancers with low incidences, such as EOC and male BC, where the population size is small, and there is no prior averaging over calendar years. The refinement will have little effect on incidences from larger countries.

Our models have certain limitations. No single dataset containing all the required information was available to construct the multifactorial models, so the models were extended via a synthetic approach. The new model parameters were taken from extensive, well-designed published studies together with existing parameters from model fitting^{9 10}. We and others have used this approach for developing previous versions of the models^{8 11 12 21 38 39}, which have been shown to provide clinically valid predictions^{40 41}. Furthermore, the BOADICEA model presented here, has been validated in a large independent study, and has been demonstrated to be well calibrated to discriminate well between affected and unaffected women [Yang et al, under review]. As is the case for the previous versions, the updates presented here are primarily based on studies of those of European ancestry in developed countries. There is little evidence that the RRs associated with PVs differ by ancestry. The PV frequencies are also broadly similar across populations, except for specific founder mutations and *CHEK2* PVs, which have a much higher frequency in European than non-European populations. However, other parameters in the model, including RF and PRS distributions, will differ by population, and the model will need to be adapted for use in non-European ancestry populations and developing countries. The synthetic approach presented here allows the model to be easily customised to other populations as better estimates become available^{42 43}.

The new model features have been built on the established and well-validated BOADICEA and EOC models^{8 11 40}. The updated models will allow for more personalised risks, thus allowing more informed choices on screening, prevention, risk factor modification or other risk-reducing options. The models are available for use by healthcare professionals through the user-friendly CanRisk webtool (www.canrisk.org).

Additional Information

Acknowledgements

Authors' contributions

Conceptualization: ACA, PPDP, DFE

Methodology: AL, ACA, DFE, PPDP

Software: AL, APC, TC, SA, FMW, MT, JR, JUS

Investigation: AL, ACA, PPDP, DFE

Formal analysis: AL, NM

Funding acquisition: ACA, MKS, PD, JS

Resources: PPDP, DFE, VZ, HJ, EF, AdP, MR, TM

Supervision: ACA

Visualisation: AL

Writing – original draft: AL, ACA, DFE

Writing – review & editing: all authors

Ethics approval and consent to participate

No ethical approval or consent was necessary for this work.

Data availability

Both models are freely available for non-commercial use through www.canrisk.org

Competing interests

The authors ACA, DFE, AL, APC and TC are named inventors of BOADICEA v5 commercialised by Cambridge Enterprise.

Funding information

This work has been supported by grants from Cancer Research UK (C12292/A20861 and PPRPGM-Nov20\100002); the European Union's Horizon 2020 research and innovation programme under grant agreement numbers 633784 (B-CAST) and 634935 (BRIDGES); the PERSPECTIVE I&I project, which the Government of Canada funds through Genome Canada

(#13529) and the Canadian Institutes of Health Research (#155865), the *Ministère de l'Économie et de l'Innovation du Québec* through Genome Québec, the Quebec Breast Cancer Foundation, the CHU de Quebec Foundation and the Ontario Research Fund.

The University of Cambridge receives salary support for PDPP from the NHS through the Clinical Academic Reserve.

This research is linked to the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which FMW is Director.

References

1. Cancer Research UK. Ovarian Cancer Statistics [Ovarian cancer statistics for the UK]. Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer> accessed 21 June 2021.
2. Cancer Research UK. Breast cancer statistics [Breast cancer statistics for the UK]. Available from: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer> accessed 21 June 2021.
3. The UK Government. Breast screening: programme overview [updated 17 March 2021]. Available from: <https://www.gov.uk/guidance/breast-screening-programme-overview> accessed 15 July 2021.
4. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nat Rev Clin Oncol* 2020;17(11):687-705. doi: 10.1038/s41571-020-0388-9 [published Online First: 2020/06/20]
5. Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, Schumacher FR, Anderson WF, Check D, Chattopadhyay S, Baglietto L, Berg CD, Chanock SJ, Cox DG, Figueroa JD, Gail MH, Graubard BI, Haiman CA, Hankinson SE, Hoover RN, Isaacs C, Kolonel LN, Le Marchand L, Lee IM, Lindstrom S, Overvad K, Romieu I, Sanchez MJ, Southey MC, Stram DO, Tumino R, VanderWeele TJ, Willett WC, Zhang S, Buring JE, Canzian F, Gapstur SM, Henderson BE, Hunter DJ, Giles GG, Prentice RL, Ziegler RG, Kraft P, Garcia-Closas M, Chatterjee N. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. *JAMA Oncol* 2016;2(10):1295-302. doi: 10.1001/jamaoncol.2016.1025
6. Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM, for Australian Cancer S, Australian Ovarian Cancer Study G, Chenevix-Trench G, Jordan SM, Stram DA, Chang-Claude J, Hein R, Nickels S, Lurie G, Thompson PJ, Carney ME, Goodman MT, Moysich K, Hogdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Vierkant RA, Weber RP, Ziogas A, Anton-Culver H, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Brinton L, Wentzensen N, Lissowska J, Garcia-Closas M, Massuger LF, Kiemenev LA, Van Altena AM, Aben KK, Berchuck A, Doherty JA, Iversen E, McGuire V, Moorman PG, Pharoah P, Pike MC, Risch H, Sieh W, Stram DO, Terry KL, Whittemore A, Wu AH, Schildkraut JM, Kjaer SK, Ovarian Cancer Association C. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 2013;22(5):880-90. doi: 10.1158/1055-9965.EPI-12-1030-T [published Online First: 2013/03/07]
7. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Lee AW, Menon U, Fasching PA, McAlpine JN, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, Huntsman DG, Wu AH, Berchuck A, Pike MC, Pharoah PD. Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiol Biomarkers Prev* 2015;24(4):671-6. doi: 10.1158/1055-9965.EPI-14-1128
8. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M,

- Tischkowitz M, Pharoah P, Easton DF, Antoniou AC. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genet Med* 2019;21(8):1708-18. doi: 10.1038/s41436-018-0406-9 [published Online First: 2019/01/16]
9. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer* 2008;98(8):1457-66. doi: 6604305 [pii];10.1038/sj.bjc.6604305 [doi]
 10. Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton DF, Jacobs I, Pharoah PP, Antoniou AC. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. *J Med Genet* 2015;52(7):465-75. doi: 10.1136/jmedgenet-2015-103077
 11. Lee A, Yang X, Tyrer J, Gentry-Maharaj A, Ryan A, Mavaddat N, Cunningham AP, Carver T, Archer S, Leslie G, Kalsi J, Gaba F, Manchanda R, Gayther SA, Ramus SJ, Walter FM, Tischkowitz M, Jacobs I, Menon U, Easton DF, Pharoah PPD, Antoniou AC. A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors. *J Med Genet* 2021:In Press.
 12. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC, Consortium of Investigators of Modifiers of B, Breast Cancer Association C. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. *Br J Cancer* 2014;110(2):535-45. doi: 10.1038/bjc.2013.730
 13. Fischer C, Kuchenbaecker K, Engel C, Zachariae S, Rhiem K, Meindl A, Rahner N, Dikow N, Plendl H, Debatin I, Grimm T, Gadzicki D, Flottmann R, Horvath J, Schrock E, Stock F, Schafer D, Schwaab I, Kartsonaki C, Mavaddat N, Schlegelberger B, Antoniou AC, Schmutzler R. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. *J Med Genet* 2013;50(6):360-67. doi: jmedgenet-2012-101415 [pii];10.1136/jmedgenet-2012-101415 [doi]
 14. Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, Roberts J, Ruston R, Walter FM, Tischkowitz M, Easton DF, Antoniou AC. CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. *Cancer Epidemiol Biomarkers Prev* 2021;30(3):469-73. doi: 10.1158/1055-9965.EPI-20-1319 [published Online First: 2020/12/19]
 15. Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortunato C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraiz B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C, Conroy DM, Decker B, Fachal L, Mavaddat N, Ahearn T, Aittomäki K, Antonenkova NN, Arnold N, Arveux P, Ausems MGEM, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Briceno I, Brüning T, Burwinkel B, Cameron DA, Camp NJ, Campbell A, Carracedo A, Castelao JE, Cessna MH, Chanock SJ, Christiansen H, Collée

- JM, Cordina-Duverger E, Cornelissen S, Czene K, Dörk T, Ekici AB, Engel C, Eriksson M, Fasching PA, Figueroa J, Flyger H, Försti A, Gabrielson M, Gago-Dominguez M, Georgoulas V, Gil F, Giles GG, Glendon G, Garcia EBG, Alnæs GIG, Guénel P, Hadjisavvas A, Haeberle L, Hahnen E, Hall P, Hamann U, Harkness EF, Hartikainen JM, Hartman M, He W, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Hollestelle A, Ho WK, Hooning MJ, Howell A, Humphreys K, Idris F, Jakubowska A, Jung A, Kapoor PM, Kerin MJ, Khusnutdinova E, Kim SW, Ko YD, Kosma VM, Kristensen VN, Kyriacou K, Lakeman IMM, Lee JW, Lee MH, Li J, Lindblom A, Lo WY, Loizidou MA, Lophatananon A, Lubiński J, MacInnis RJ, Madsen MJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, Mavroudis D, McLean C, Meindl A, Mensenkamp AR, Michailidou K, Miller N, Mohd Taib NA, Muir K, Mulligan AM, Nevanlinna H, Newman WG, Nordestgaard BG, Ng PS, Oosterwijk JC, Park SK, Park-Simon TW, Perez JIA, Peterlongo P, Porteous DJ, Prajzandanc K, Prokofyeva D, Radice P, Rashid MU, Rhenius V, Rookus MA, Rüdiger T, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Schürmann P, Shah M, Sohn C, Southey MC, Surowy H, Suvanto M, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tzardi M, Valova Y, van Asperen CJ, Van Dam RM, van den Ouweland AMW, van der Kolk LE, van Veen EM, Wendt C, Williams JA, Yang XR, Yoon SY, Zamora MP, Evans DG, de la Hoya M, Simard J, Antoniou AC, Borg Å, Andrulis IL, Chang-Claude J, García-Closas M, Chenevix-Trench G, Milne RL, Pharoah PDP, Schmidt MK, Spurdle AB, Vreeswijk MPG, Benitez J, Dunning AM, Kvist A, Teo SH, Devilee P, Easton DF, Consortium BCA. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med* 2021;384(5):428-39. doi: 10.1056/NEJMoa1913948 [published Online First: 2021/01/20]
16. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ, Samara R, Klebba J, Ambrosone CB, Anton-Culver H, Auer P, Bandera EV, Bernstein L, Bertrand KA, Burnside ES, Carter BD, Eliassen H, Gapstur SM, Gaudet M, Haiman C, Hodge JM, Hunter DJ, Jacobs EJ, John EM, Kooperberg C, Kurian AW, Le Marchand L, Lindstroem S, Lindstrom T, Ma H, Neuhausen S, Newcomb PA, O'Brien KM, Olson JE, Ong IM, Pal T, Palmer JR, Patel AV, Reid S, Rosenberg L, Sandler DP, Scott C, Tamimi R, Taylor JA, Trentham-Dietz A, Vachon CM, Weinberg C, Yao S, Ziogas A, Weitzel JN, Goldgar DE, Domchek SM, Nathanson KL, Kraft P, Polley EC, Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. *N Engl J Med* 2021;384(5):440-51. doi: 10.1056/NEJMoa2005936 [published Online First: 2021/01/21]
17. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomaki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg A, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkas K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J,

- Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmana J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo SH, Robson M, Pal T, Couch F, Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, Tischkowitz M. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. *J Clin Oncol* 2020;38(7):674-85. doi: 10.1200/JCO.19.01907 [published Online First: 2019/12/17]
18. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, Rossing MA, Duerst M, Dork T, Bogdanova NV, Modugno F, Moysich K, Odunsi K, Ness R, Karlan BY, Lester J, Jensen A, Kruger Kjaer S, Hogdall E, Campbell IG, Lazaro C, Pujara MA, Cunningham J, Vierkant R, Winham SJ, Hildebrandt M, Huff C, Li D, Wu X, Yu Y, Permut JB, Levine DA, Schildkraut JM, Riggan MJ, Berchuck A, Webb PM, Group OS, Cybulski C, Gronwald J, Jakubowska A, Lubinski J, Alsop J, Harrington P, Chan I, Menon U, Pearce CL, Wu AH, de Fazio A, Kennedy CJ, Goode E, Ramus S, Gayther S, Pharoah P. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. *J Med Genet* 2021;58(5):305-13. doi: 10.1136/jmedgenet-2019-106739 [published Online First: 2020/06/18]
 19. Mavaddat N. *et al.* Pathology of tumors associated with pathogenic germline variants in nine breast cancer susceptibility genes. *JAMA Oncol*:In Press.
 20. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. *Breast Cancer Res* 2010;12(3):R28. doi: bcr2576 [pii];10.1186/bcr2576 [doi]
 21. Lee AJ, Cunningham AP, Tischkowitz M, Simard J, Pharoah PD, Easton DF, Antoniou AC. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. *Genet Med* 2016 doi: 10.1038/gim.2016.31
 22. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. *Br J Cancer* 2004;91(8):1580-90. doi: 10.1038/sj.bjc.6602175 [doi];6602175 [pii]
 23. Garcia-Closas M, Gunsoy NB, Chatterjee N. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. *J Natl Cancer Inst* 2014;106(11):dju305. doi: 10.1093/jnci/dju305
 24. Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horvath J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomaki K, Pelttari LM, Ehrencrona H, Borg A, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, Dennis J, Bowtell DD, Traficante N, Diez O, Balmana J, Gruber SB, Chenevix-Trench G, kConFab I, Jensen A, Kjaer SK, Hogdall E, Castera L, Garber J, Janavicius R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler RK, Pharoah PDP, Antoniou AC. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. *J Natl Cancer Inst* 2020 doi: 10.1093/jnci/djaa030 [published Online First: 2020/02/29]
 25. National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer

- and related risks in people with a family history of breast cancer (CG164) 2013 [updated 2019-11-20. Available from: <http://www.nice.org.uk/CG164>.
26. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomaki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Bruning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collee JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dork T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Forsti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, Garcia-Saenz JA, Gaudet MM, Georgoulas V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, Gonzalez-Neira A, Grenaker Alnaes GI, Grip M, Gronwald J, Grundy A, Guenel P, Haeberle L, Hahnen E, Haiman CA, Hakansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Kruger U, Kuhl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Lilyquist J, Lindblom A, Lindstrom S, Lissowska J, Lo WY, Loibl S, Long J, Lubinski J, Lux MP, Maclinnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Munoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Perez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkas K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schurmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thone K, Tollenaar R, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A, Investigators A, kConFab AI, Collaborators N, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, Garcia-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet* 2019;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002
27. Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for

- ovarian cancer prevention: a cost-effectiveness analysis. *J Med Genet* 2016;53(9):591-9. doi: 10.1136/jmedgenet-2016-103800
28. Manchanda R, Legood R, Pearce L, Menon U. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. *Gynecol Oncol* 2015;139(3):487-94. doi: 10.1016/j.ygyno.2015.10.001
29. Dareng EO, Tyrer J, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata SA, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton J, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew Y-E, Chung WK, Claes KBM, Colonna S, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans DG, Fasching P, Flanagan JM, Foretova L, Fortner RT, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang R-Y, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Anna Jakubowska A, James P, Janavicius R, Jensen A, Johannsson OT, John EM, Jones M, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim B-G, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine D, Li L, Li J, Loud JT, Lu KH, Lubiński J, Machackova E, Mai PL, Manoukian S, Marks J, Kim Matsuno R, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Ngeow Yuen Yie J, Roed Nielsen H, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan M, Risch HB, Rodriguez-Antona C, Ross EA, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko A, Song H, Southey M, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira M, Teo SH, Terry KL, Terry MB, Thomassen M, Thompson PJ, Thomsen LC, Hull DL, Tischkowitz M, Titus L, Toland A, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Velez Edwards D, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo Y-L, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Easton D, Lawrenson K, deFazio A, Sellers TA, Ramus SJ, Pearce C, Montiero AN, Cunningham JM, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk. *Eur J Hum Genet* 2021:In Press.
30. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. *Genet Epidemiol* 2001;21(1):1-18. doi: 10.1002/gepi.1014 [pii];10.1002/gepi.1014 [doi]

31. Muranen TA, Greco D, Blomqvist C, Aittomaki K, Khan S, Hogervorst F, Verhoef S, Pharoah PDP, Dunning AM, Shah M, Luben R, Bojesen SE, Nordestgaard BG, Schoemaker M, Swerdlow A, Garcia-Closas M, Figueroa J, Dork T, Bogdanova NV, Hall P, Li J, Khusnutdinova E, Bermisheva M, Kristensen V, Borresen-Dale AL, Investigators N, Peto J, Dos Santos Silva I, Couch FJ, Olson JE, Hillemans P, Park-Simon TW, Brauch H, Hamann U, Burwinkel B, Marme F, Meindl A, Schmutzler RK, Cox A, Cross SS, Sawyer EJ, Tomlinson I, Lambrechts D, Moisse M, Lindblom A, Margolin S, Hollestelle A, Martens JWM, Fasching PA, Beckmann MW, Andrulis IL, Knight JA, Investigators K, Anton-Culver H, Ziogas A, Giles GG, Milne RL, Brenner H, Arndt V, Mannermaa A, Kosma VM, Chang-Claude J, Rudolph A, Devilee P, Seynaeve C, Hopper JL, Southey MC, John EM, Whittemore AS, Bolla MK, Wang Q, Michailidou K, Dennis J, Easton DF, Schmidt MK, Nevanlinna H. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genet Med* 2017;19(5):599-603. doi: 10.1038/gim.2016.147
32. Gao C, Polley EC, Hart SN, Huang H, Hu C, Gnanaolivu R, Lilyquist J, Boddicker NJ, Na J, Ambrosone CB, Auer PL, Bernstein L, Burnside ES, Eliassen AH, Gaudet MM, Haiman C, Hunter DJ, Jacobs EJ, John EM, Lindstrom S, Ma H, Neuhausen SL, Newcomb PA, O'Brien KM, Olson JE, Ong IM, Patel AV, Palmer JR, Sandler DP, Tamimi R, Taylor JA, Teras LR, Trentham-Dietz A, Vachon CM, Weinberg CR, Yao S, Weitzel JN, Goldgar DE, Domchek SM, Nathanson KL, Couch FJ, Kraft P. Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. *J Clin Oncol* 2021;JCO2001992. doi: 10.1200/JCO.20.01992 [published Online First: 2021/06/09]
33. Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. *JAMA Netw Open* 2020;3(7):e208501. doi: 10.1001/jamanetworkopen.2020.8501 [published Online First: 2020/07/02]
34. Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindstrom S, Behrens S, Michailidou K, Dennis J, Bolla MK, Wang Q, Jung A, Abu-Ful Z, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Freeman LEB, Becher H, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernstein L, Bojesen SE, Brauch H, Brenner H, Bruning T, Cai Q, Campa D, Canzian F, Carracedo A, Carter BD, Castelao JE, Chanock SJ, Chatterjee N, Chenevix-Trench G, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dai JY, Earp HS, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, Gaudet MM, Giles GG, Gonzalez-Neira A, Guenel P, Haeberle L, Haiman CA, Hakansson N, Hall P, Hamann U, Hatse S, Heyworth J, Holleczeck B, Hoover RN, Hopper JL, Howell A, Hunter DJ, Investigators A, kConFab AI, John EM, Jones ME, Kaaks R, Keeman R, Kitahara CM, Ko YD, Koutros S, Kurian AW, Lambrechts D, Le Marchand L, Lee E, Lejbkovicz F, Linet M, Lissowska J, Llana A, Maclnnis RJ, Martinez ME, Maurer T, McLean C, Neuhausen SL, Newman WG, Norman A, O'Brien KM, Olshan AF, Olson JE, Olsson H, Orr N, Perou CM, Pita G, Polley EC, Prentice RL, Rennert G, Rennert HS, Ruddy KJ, Sandler DP, Saunders C, Schoemaker MJ, Schottker B, Schumacher F, Scott C, Scott RJ, Shu XO, Smeets A, Southey MC, Spinelli JJ, Stone J, Swerdlow AJ, Tamimi RM, Taylor JA, Troester MA, Vachon CM, van Veen EM, Wang X, Weinberg CR, Weltens C, Willett W, Winham SJ, Wolk A, Yang XR, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Schmidt MK, Kraft P, Easton DF, Milne RL, Garcia-Closas M, Chang-Claude J.

- Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *J Natl Cancer Inst* 2021;113(3):329-37. doi: 10.1093/jnci/djaa056 [published Online First: 2020/05/03]
35. Eriksson M, Li J, Leifland K, Czene K, Hall P. A comprehensive tool for measuring mammographic density changes over time. *Breast cancer research and treatment* 2018;169(2):371-79. doi: 10.1007/s10549-018-4690-5 [published Online First: 2018/02/03]
 36. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. *Phys Med Biol* 1994;39(10):1629-38. doi: 10.1088/0031-9155/39/10/008 [published Online First: 1994/10/01]
 37. Astley SM, Harkness EF, Sergeant JC, Warwick J, Stavrinou P, Warren R, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Brentnall AR, Cuzick J, Howell T, Evans DG. A comparison of five methods of measuring mammographic density: a case-control study. *Breast Cancer Res* 2018;20(1):10. doi: 10.1186/s13058-018-0932-z [published Online First: 2018/02/07]
 38. Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. *Nat Rev Genet* 2016;17(7):392-406. doi: 10.1038/nrg.2016.27
 39. Pal Choudhury P, Maas P, Wilcox A, Wheeler W, Brook M, Check D, Garcia-Closas M, Chatterjee N. iCARE: An R package to build, validate and apply absolute risk models. *PLoS One* 2020;15(2):e0228198. doi: 10.1371/journal.pone.0228198 [published Online First: 2020/02/05]
 40. Pal Choudhury P, Brook MN, Hurson AN, Lee A, Mulder CV, Coulson P, Schoemaker MJ, Jones ME, Swerdlow AJ, Chatterjee N, Antoniou AC, Garcia-Closas M. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. *Breast Cancer Res* 2021;23(1):22. doi: 10.1186/s13058-021-01399-7 [published Online First: 2021/02/15]
 41. Pal Choudhury P, Wilcox AN, Brook MN, Zhang Y, Ahearn T, Orr N, Coulson P, Schoemaker MJ, Jones ME, Gail MH, Swerdlow AJ, Chatterjee N, Garcia-Closas M. Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification. *J Natl Cancer Inst* 2020;112(3):278-85. doi: 10.1093/jnci/djz113 [published Online First: 2019/06/06]
 42. Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Ho PJ, Dennis J, Tyrer JP, Bolla MK, Michailidou K, Wang Q, Kang D, Choi JY, Jamaris S, Shu XO, Yoon SY, Park SK, Kim SW, Shen CY, Yu JC, Tan EY, Chan PMY, Muir K, Lophatananon A, Wu AH, Stram DO, Matsuo K, Ito H, Chan CW, Ngeow J, Yong WS, Lim SH, Lim GH, Kwong A, Chan TL, Tan SM, Seah J, John EM, Kurian AW, Koh WP, Khor CC, Iwasaki M, Yamaji T, Tan KMV, Tan KTB, Spinelli JJ, Aronson KJ, Hasan SN, Rahmat K, Vijayanathan A, Sim X, Pharoah PDP, Zheng W, Dunning AM, Simard J, van Dam RM, Yip CH, Taib NAM, Hartman M, Easton DF, Teo SH, Antoniou AC. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nat Commun* 2020;11(1):3833. doi: 10.1038/s41467-020-17680-w [published Online First: 2020/08/02]
 43. Shieh Y, Fejerman L, Lott PC, Marker K, Sawyer SD, Hu D, Huntsman S, Torres J, Echeverry M, Bohorquez ME, Martinez-Chequer JC, Polanco-Echeverry G, Estrada-Florez AP, Consortium C, Haiman CA, John EM, Kushi LH, Torres-Mejia G, Vidaurre T,

- Weitzel JN, Zambrano SC, Carvajal-Carmona LG, Ziv E, Neuhausen SL. A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women. *J Natl Cancer Inst* 2020;112(6):590-98. doi: 10.1093/jnci/djz174 [published Online First: 2019/09/26]
44. Lee A, Yang X, Tyrer J, Gentry-Maharaj A, Ryan A, Mavaddat N, Cunningham AP, Carver T, Archer S, Leslie G, Kalsi J, Gaba F, Manchanda R, Gayther SA, Ramus SJ, Walter FM, Tischkowitz M, Jacobs I, Menon U, Easton DF, Pharoah PPD, Antoniou AC. A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors. *medRxiv* 2021:2020.12.04.20244046. doi: 10.1101/2020.12.04.20244046

Figure Legends

Figure 1: Predicted risk by age Vs age for a female born in 1985 with an unknown family history based on pathogenic variant carrier status for the new genes in the model. Figure (a) shows the breast cancer risk for carriers of pathogenic variants in *BARD1*, *RAD51C* and *RAD51D* along with the population risk. Figure (b) shows the ovarian cancer risk for carriers of pathogenic variants in *PALB2* along with the population risk. Predictions are based on UK cancer incidences.

Figure 2. Predicted lifetime cancer risks (from age 20 to 80 years) for a female born in 1985 with a pathogenic variant in *BARD1* (breast cancer risk), *RAD51C* (breast cancer risk), *RAD51D* (breast cancer risk), and *PALB2* (ovarian cancer risk) on the basis of the different predictors of risk (pathogenic variant status (PV), questionnaire-based risk factors (QRFs), mammographic density (MD), and PRS). All figures show the probability density against the absolute risk. Figures (a), (c), (e) and (g) show risks for a female with unknown family history, while Figures (b), (d), (f) and (h) show risks where the individual's mother has had cancer at age 50. The backgrounds of the graphs are shaded to indicate the risk categories. For breast cancer, these are the categories defined by the National Institute for Health and Care Excellence familial breast cancer guidelines²⁵: 1) near-population risk shaded in pink (<17%), 2) moderate risk shaded in yellow ($\geq 17\%$ and <30%) and 3) high risk shaded in blue ($\geq 30\%$). For ovarian cancer, the categories are: 1) near-population risk shaded in pink (<5%), 2) moderate risk shaded in yellow ($\geq 5\%$ and <10%) and 3) high risk shaded in blue ($\geq 10\%$). Predictions were based on UK cancer incidences. The line labelled population denotes the average population risk in the absence of knowledge of family history, pathogenic variant status, RFs or a PRS.

Figure 3. The tumour pathology proportions in the general population and among carriers of pathogenic variants (PV) in the breast cancer (BC) susceptibility genes included in the BOADICEA model. Figure (a) shows the proportion of oestrogen receptor-negative (ER-) tumours among all tumours, and Figure (b) shows the proportion of triple-negative (TN) (ER-, progesterone receptor-negative and human epidermal growth factor receptor 2) tumours among ER- tumours. The general population, *BRCA1* PV and *BRCA2* PV values are the same

as previously used in the model¹², while those for the other genes are updated using recent BRIDGES data¹⁹.

Figure 4: The probabilities of carrying a pathogenic variant estimated by BOADICEA in the genes *PALB2*, *CHEK2*, *ATM*, *BARD1*, *RAD51C* and *RAD51D* for an affected female born in 1985 as a function of her age at diagnosis based on different tumour pathology. Figures (a), (c), (e) and (g) show the probabilities based on the updated proportions, while figures (b), (d), (f) and (h) are based on the previous proportions and where proportions for *BARD1*, *RAD51C* and *RAD51D*, which were not in the previous model, are assumed to be the same as in the general population. In figures (a) and (b), the female has had an oestrogen receptor-positive (ER+) tumour; in figures (c) and (d), the female has had an oestrogen receptor-negative (ER-) tumour, but the triple-negative (TN) status is unknown; in figures (e) and (f), the female has had an ER- tumour that is not TN and in figures (g) and (h), the female has had a TN tumour. Predictions are based on UK cancer incidences.

Figure 5. Predicted lifetime breast and ovarian cancer risks as a function of height for a female born in 1985 with unknown family history, comparing the updated model, where height is treated as continuous, to the previous model, where height was treated as categorical. Figures (a), (c) and (e) show breast cancer, while Figures (b), (d) and (f) show ovarian cancer risks. Figures (a) and (b) show the predicted risk as a function of height, while Figures (c) and (d) show the probability density/mass of risk as a function of height. Predictions are based on UK cancer incidences. Figures (e) and (f) show the log (base 10) of the root-mean-squared relative discretisation error as a function of the number of bins. The error was taken to be the absolute difference between the value and the asymptotic extrapolation of the measurements as a function of the number of bins. The average is taken over 100 heights that are spaced 1% apart, from 0.5% to 99.5%.

Table 1. The parameters used to include the effects of rare high- and intermediate-risk pathogenic variants in the models.

GENE	ALLELE FREQ	SS	RR OF FEMALE BREAST CANCER (95% CI)	RROF EOC (95% CI)	RR OF MALE BREAST CANCER (95% CI)	RR OF PROSTATE CANCER	RR OF PANCREATIC CANCER (95% CI)			
BRCA1	BOADICEA 0.0006394	0.89	1 age < 20 exp(3.0146 + 0.02412 × age) 20 ≤ age ≤ 29 exp(6.0707 - 0.07775 × age) 30 ≤ age ≤ 39 exp(4.2511 - 0.03226 × age) 40 ≤ age ≤ 49 exp(4.2086 - 0.03141 × age) 50 ≤ age ≤ 79	1 age < 30 exp(-3.55 + 0.1986 × age) 30 ≤ age ≤ 39 exp(7.1776 - 0.06959 × age) 40 ≤ age ≤ 49 exp(4.5236 - 0.01651 × age) 50 ≤ age ≤ 79	8	1.82 age < 65 0.84 age ≥ 65	3.10 age < 65 1.54 age ≥ 65			
	EOC Model 0.0007947									
BRCA2	BOADICEA 0.00102	0.96	1 age < 20 exp(3.2153 - 0.008815 × age) 20 ≤ age ≤ 29 exp(4.28945 - 0.04462 × age) 30 ≤ age ≤ 39 exp(3.96865 - 0.0366 × age) 40 ≤ age ≤ 49 exp(1.8169 + 0.006435 × age) 50 ≤ age ≤ 59 exp(-0.2606 + 0.04106 × age) 60 ≤ age ≤ 69 13.0991 70 ≤ age ≤ 79	1 age < 40 exp(-9.708 + 0.2427 × age) 40 ≤ age ≤ 53 exp(6.50334 - 0.05751 × age) 54 ≤ age ≤ 57 exp(17.41836 - 0.2457 × age) 58 ≤ age ≤ 69 1.5921 70 ≤ age ≤ 79	80	7.33 age < 65 3.39 age ≥ 65	5.54 age < 65 1.61 age ≥ 65			
	EOC Model 0.002576									
PALB2	0.00064	0.92	1 age < 20 9.1 20 ≤ age ≤ 24 8.97 25 ≤ age ≤ 29 8.85 30 ≤ age ≤ 34 8.54 35 ≤ age ≤ 39 8.02 40 ≤ age ≤ 44 7.31 45 ≤ age ≤ 49 6.55 50 ≤ age ≤ 54 5.92 55 ≤ age ≤ 59 5.45 60 ≤ age ≤ 64 5.10 65 ≤ age ≤ 69 4.82 70 ≤ age ≤ 74 4.56 75 ≤ age ≤ 79	1 age < 30 2.91 (1.40 - 6.04) age ≥ 30	1 age < 30 7.34 (1.28 - 42.18) age ≥ 30	1	1 age < 30 2.37 (1.24 - 4.50) age ≥ 30			
			CHEK2	0.00373	0.98	1 age < 20 exp(-1.605325 - 0.0148367 × age) age ≥ 20	1	1	1	
			ATM	0.0018	0.94	2.10 (1.17 - 2.57)	1	1	1	
			BARD1	0.00043	0.89	2.09 (1.35 - 3.23)	1	1	1	
			RAD51C	0.00035	0.78	1.97 (1.48 - 2.62)	1 age < 30 exp(-1.7974 + 0.07631 × age) 30 ≤ age < 60 exp(9.7592 - 0.1163 × age) age ≥ 60	1	1	1
						RAD51D	0.00035	0.86	1.82 (1.34 - 2.47)	1 age < 30 exp(-2.88662 + 0.09656 × age) 30 ≤ age < 58 exp(5.99144 - 0.05651 × age) age ≥ 58
			BRIP1	0.00071	0.95	1	3.41 (2.12 - 5.54)	1	1	1

“Allele Freq” is the pathogenic variant allele frequency in the general population, SS is the screening sensitivity, RR is the relative risk, relative to the general population and EOC is epithelial tubo-ovarian cancer. The BOADICEA model includes the effects of *BRCA1*, *BRCA2*, *PALB2*, *CHEK2*, *ATM*, *BARD1*, *RAD51C* and *RAD51D*, while the EOC Model includes the effects of *BRCA1*, *BRCA2*, *RAD51D*, *RAD51C*, *BRIP1* and *PALB2*. The updated parameters are the allele frequencies for *PALB2*, *CHEK2*, *ATM*, *RAD51C*, *RAD51D*, *BRIP1* and *BRIP1*¹⁵, the SS for pathogenic

variants in for all genes¹⁵, the RR for female breast cancer for *ATM*, *BARD1*, *RAD51C* and *RAD51D*^{15 24}, and the EOC, male breast cancer and the pancreatic cancer RRs for *PALB2*¹⁷. All other parameters are as previously published^{8-10 21 44}.






Figure 1


(a)




(b)




(a)




(b)




(c)




(d)




(e)




(f)




(g)



(h)




(a)




(b)


Figure 3




(a)




(b)




(c)




(d)




(e)




(f)




(g)




(h)




(a)




(b)




(c)



(d)



(e)



(f)